Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. / Fotheringham, Amelia K.; Bagger, Jonatan I.; Borg, Danielle J.; McCarthy, Domenica A.; Holst, Jens J.; Vilsbøll, Tina; Knop, Filip K.; Forbes, Josephine M.

I: Nutrients, Bind 12, Nr. 10, 2928, 2020.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Fotheringham, AK, Bagger, JI, Borg, DJ, McCarthy, DA, Holst, JJ, Vilsbøll, T, Knop, FK & Forbes, JM 2020, 'Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes', Nutrients, bind 12, nr. 10, 2928. https://doi.org/10.3390/nu12102928

APA

Fotheringham, A. K., Bagger, J. I., Borg, D. J., McCarthy, D. A., Holst, J. J., Vilsbøll, T., Knop, F. K., & Forbes, J. M. (2020). Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. Nutrients, 12(10), [2928]. https://doi.org/10.3390/nu12102928

Vancouver

Fotheringham AK, Bagger JI, Borg DJ, McCarthy DA, Holst JJ, Vilsbøll T o.a. Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. Nutrients. 2020;12(10). 2928. https://doi.org/10.3390/nu12102928

Author

Fotheringham, Amelia K. ; Bagger, Jonatan I. ; Borg, Danielle J. ; McCarthy, Domenica A. ; Holst, Jens J. ; Vilsbøll, Tina ; Knop, Filip K. ; Forbes, Josephine M. / Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. I: Nutrients. 2020 ; Bind 12, Nr. 10.

Bibtex

@article{94429fda3e7b4dd09a68866ea1d30c02,
title = "Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes",
abstract = "Postprandial glucose excursions are postulated to increase the risk for diabetes complications via the production of advanced glycation end products (AGEs). The soluble receptor of AGEs (sRAGE) likely acts as a decoy receptor, mopping up AGEs, diminishing their capacity for pro-inflammatory and pro-apoptotic signaling. Recent evidence suggests that AGEs and soluble receptor for AGEs (sRAGE) may be altered under postprandial and fasting conditions. Here, we investigated the effects of increasing oral glucose loads during oral glucose tolerance tests (OGTT) and matched isoglycaemic intravenous (i.v.) glucose infusions (IIGI) on circulating concentrations of sRAGE. Samples from eight individuals with type 2 diabetes and eight age-, gender-, and body mass index (BMI)-matched controls, all of whom underwent three differently dosed OGTTs (25 g, 75 g, and 125 g), and three matched IIGIs were utilised (NCT00529048). Serum concentrations of sRAGE were measured over 240 min during each test. For individuals with diabetes, sRAGE area under the curve (AUC0-240min) declined with increasing i.v. glucose dosages (p < 0.0001 for trend) and was lower during IIGI compared to OGTT at the 125 g dosage (p = 0.004). In control subjects, sRAGE AUC0-240min was only lower during IIGI compared to OGTT at the 25 g dose (p = 0.0015). sRAGE AUC0-240min was negatively correlated to AUC0-240min for the incretin hormone glucagon-like peptide -1 (GLP-1) during the 75 g OGTT and matched IIGI, but only in individuals with type 2 diabetes. These data suggest that gastrointestinal factors may play a role in regulating sRAGE concentrations during postprandial glucose excursions, thus warranting further investigation.",
keywords = "AGEs, diabetes complications, enteroendocrine, metabolic alterations of T2DM, RAGE, sRAGE, type 2 diabetes mellitus",
author = "Fotheringham, {Amelia K.} and Bagger, {Jonatan I.} and Borg, {Danielle J.} and McCarthy, {Domenica A.} and Holst, {Jens J.} and Tina Vilsb{\o}ll and Knop, {Filip K.} and Forbes, {Josephine M.}",
year = "2020",
doi = "10.3390/nu12102928",
language = "English",
volume = "12",
journal = "Nutrients",
issn = "2072-6643",
publisher = "M D P I AG",
number = "10",

}

RIS

TY - JOUR

T1 - Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes

AU - Fotheringham, Amelia K.

AU - Bagger, Jonatan I.

AU - Borg, Danielle J.

AU - McCarthy, Domenica A.

AU - Holst, Jens J.

AU - Vilsbøll, Tina

AU - Knop, Filip K.

AU - Forbes, Josephine M.

PY - 2020

Y1 - 2020

N2 - Postprandial glucose excursions are postulated to increase the risk for diabetes complications via the production of advanced glycation end products (AGEs). The soluble receptor of AGEs (sRAGE) likely acts as a decoy receptor, mopping up AGEs, diminishing their capacity for pro-inflammatory and pro-apoptotic signaling. Recent evidence suggests that AGEs and soluble receptor for AGEs (sRAGE) may be altered under postprandial and fasting conditions. Here, we investigated the effects of increasing oral glucose loads during oral glucose tolerance tests (OGTT) and matched isoglycaemic intravenous (i.v.) glucose infusions (IIGI) on circulating concentrations of sRAGE. Samples from eight individuals with type 2 diabetes and eight age-, gender-, and body mass index (BMI)-matched controls, all of whom underwent three differently dosed OGTTs (25 g, 75 g, and 125 g), and three matched IIGIs were utilised (NCT00529048). Serum concentrations of sRAGE were measured over 240 min during each test. For individuals with diabetes, sRAGE area under the curve (AUC0-240min) declined with increasing i.v. glucose dosages (p < 0.0001 for trend) and was lower during IIGI compared to OGTT at the 125 g dosage (p = 0.004). In control subjects, sRAGE AUC0-240min was only lower during IIGI compared to OGTT at the 25 g dose (p = 0.0015). sRAGE AUC0-240min was negatively correlated to AUC0-240min for the incretin hormone glucagon-like peptide -1 (GLP-1) during the 75 g OGTT and matched IIGI, but only in individuals with type 2 diabetes. These data suggest that gastrointestinal factors may play a role in regulating sRAGE concentrations during postprandial glucose excursions, thus warranting further investigation.

AB - Postprandial glucose excursions are postulated to increase the risk for diabetes complications via the production of advanced glycation end products (AGEs). The soluble receptor of AGEs (sRAGE) likely acts as a decoy receptor, mopping up AGEs, diminishing their capacity for pro-inflammatory and pro-apoptotic signaling. Recent evidence suggests that AGEs and soluble receptor for AGEs (sRAGE) may be altered under postprandial and fasting conditions. Here, we investigated the effects of increasing oral glucose loads during oral glucose tolerance tests (OGTT) and matched isoglycaemic intravenous (i.v.) glucose infusions (IIGI) on circulating concentrations of sRAGE. Samples from eight individuals with type 2 diabetes and eight age-, gender-, and body mass index (BMI)-matched controls, all of whom underwent three differently dosed OGTTs (25 g, 75 g, and 125 g), and three matched IIGIs were utilised (NCT00529048). Serum concentrations of sRAGE were measured over 240 min during each test. For individuals with diabetes, sRAGE area under the curve (AUC0-240min) declined with increasing i.v. glucose dosages (p < 0.0001 for trend) and was lower during IIGI compared to OGTT at the 125 g dosage (p = 0.004). In control subjects, sRAGE AUC0-240min was only lower during IIGI compared to OGTT at the 25 g dose (p = 0.0015). sRAGE AUC0-240min was negatively correlated to AUC0-240min for the incretin hormone glucagon-like peptide -1 (GLP-1) during the 75 g OGTT and matched IIGI, but only in individuals with type 2 diabetes. These data suggest that gastrointestinal factors may play a role in regulating sRAGE concentrations during postprandial glucose excursions, thus warranting further investigation.

KW - AGEs

KW - diabetes complications

KW - enteroendocrine

KW - metabolic alterations of T2DM

KW - RAGE

KW - sRAGE

KW - type 2 diabetes mellitus

U2 - 10.3390/nu12102928

DO - 10.3390/nu12102928

M3 - Journal article

C2 - 32987824

AN - SCOPUS:85092070324

VL - 12

JO - Nutrients

JF - Nutrients

SN - 2072-6643

IS - 10

M1 - 2928

ER -

ID: 250385815